Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients

Matthew R. Brier; Suzanne E. Schindler; Amber Salter; Dana Perantie; Nicole Shelley; Bradley Judge; Sarah Keefe; Kristopher M. Kirmess; Philip B. Verghese; Kevin E. Yarasheski; Venky Venkatesh; Cyrus A. Raji; Brian A. Gordon; Randall J. Bateman; John C. Morris; Robert T. Naismith; David M. Holtzman; Tammie L.S. Benzinger; Anne H. Cross

doi:10.1002/ana.27027

Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients

Matthew R. Brier, Suzanne E. Schindler, Amber Salter, Dana Perantie, Nicole Shelley, Bradley Judge, Sarah Keefe, Kristopher M. Kirmess, Philip B. Verghese, Kevin E. Yarasheski, Venky Venkatesh, Cyrus A. Raji, Brian A. Gordon, Randall J. Bateman, John C. Morris, Robert T. Naismith, David M. Holtzman, Tammie L.S. Benzinger, Anne H. Cross

Research output: Contribution to journal › Article › peer-review

Abstract

The life expectancy of people with multiple sclerosis (MS) has increased, yet we have noted that development of a typical Alzheimer disease dementia syndrome is uncommon. We hypothesized that Alzheimer disease pathology is uncommon in MS patients. In 100 MS patients, the rate of amyloid-β plasma biomarker positivity was approximately half the rate in 300 non-MS controls matched on age, sex, apolipoprotein E proteotype, and cognitive status. Interestingly, most MS patients who did have amyloid-β pathology had features atypical for MS at diagnosis. These results support that MS is associated with reduced Alzheimer disease risk, and suggest new avenues of research. ANN NEUROL 2024;96:453–459.

Original language	English
Pages (from-to)	453-459
Number of pages	7
Journal	Annals of neurology
Volume	96
Issue number	3
DOIs	https://doi.org/10.1002/ana.27027
State	Published - Sep 2024

Access to Document

10.1002/ana.27027

Cite this

Brier, M. R., Schindler, S. E., Salter, A., Perantie, D., Shelley, N., Judge, B., Keefe, S., Kirmess, K. M., Verghese, P. B., Yarasheski, K. E., Venkatesh, V., Raji, C. A., Gordon, B. A., Bateman, R. J., Morris, J. C., Naismith, R. T., Holtzman, D. M., Benzinger, T. L. S., & Cross, A. H. (2024). Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients. Annals of neurology, 96(3), 453-459. https://doi.org/10.1002/ana.27027

@article{91bfb82479cd47b3aa6c0dd34c916cbc,

title = "Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients",

abstract = "The life expectancy of people with multiple sclerosis (MS) has increased, yet we have noted that development of a typical Alzheimer disease dementia syndrome is uncommon. We hypothesized that Alzheimer disease pathology is uncommon in MS patients. In 100 MS patients, the rate of amyloid-β plasma biomarker positivity was approximately half the rate in 300 non-MS controls matched on age, sex, apolipoprotein E proteotype, and cognitive status. Interestingly, most MS patients who did have amyloid-β pathology had features atypical for MS at diagnosis. These results support that MS is associated with reduced Alzheimer disease risk, and suggest new avenues of research. ANN NEUROL 2024;96:453–459.",

author = "Brier, {Matthew R.} and Schindler, {Suzanne E.} and Amber Salter and Dana Perantie and Nicole Shelley and Bradley Judge and Sarah Keefe and Kirmess, {Kristopher M.} and Verghese, {Philip B.} and Yarasheski, {Kevin E.} and Venky Venkatesh and Raji, {Cyrus A.} and Gordon, {Brian A.} and Bateman, {Randall J.} and Morris, {John C.} and Naismith, {Robert T.} and Holtzman, {David M.} and Benzinger, {Tammie L.S.} and Cross, {Anne H.}",

note = "Publisher Copyright: {\textcopyright} 2024 American Neurological Association.",

year = "2024",

month = sep,

doi = "10.1002/ana.27027",

language = "English",

volume = "96",

pages = "453--459",

journal = "Annals of neurology",

issn = "0364-5134",

number = "3",

}

Brier, MR , Schindler, SE, Salter, A, Perantie, D, Shelley, N, Judge, B, Keefe, S, Kirmess, KM, Verghese, PB, Yarasheski, KE, Venkatesh, V, Raji, CA , Gordon, BA , Bateman, RJ , Morris, JC , Naismith, RT , Holtzman, DM , Benzinger, TLS & Cross, AH 2024, 'Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients', Annals of neurology, vol. 96, no. 3, pp. 453-459. https://doi.org/10.1002/ana.27027

TY - JOUR

T1 - Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients

AU - Brier, Matthew R.

AU - Schindler, Suzanne E.

AU - Salter, Amber

AU - Perantie, Dana

AU - Shelley, Nicole

AU - Judge, Bradley

AU - Keefe, Sarah

AU - Kirmess, Kristopher M.

AU - Verghese, Philip B.

AU - Yarasheski, Kevin E.

AU - Venkatesh, Venky

AU - Raji, Cyrus A.

AU - Gordon, Brian A.

AU - Bateman, Randall J.

AU - Morris, John C.

AU - Naismith, Robert T.

AU - Holtzman, David M.

AU - Benzinger, Tammie L.S.

AU - Cross, Anne H.

PY - 2024/9

Y1 - 2024/9

N2 - The life expectancy of people with multiple sclerosis (MS) has increased, yet we have noted that development of a typical Alzheimer disease dementia syndrome is uncommon. We hypothesized that Alzheimer disease pathology is uncommon in MS patients. In 100 MS patients, the rate of amyloid-β plasma biomarker positivity was approximately half the rate in 300 non-MS controls matched on age, sex, apolipoprotein E proteotype, and cognitive status. Interestingly, most MS patients who did have amyloid-β pathology had features atypical for MS at diagnosis. These results support that MS is associated with reduced Alzheimer disease risk, and suggest new avenues of research. ANN NEUROL 2024;96:453–459.

AB - The life expectancy of people with multiple sclerosis (MS) has increased, yet we have noted that development of a typical Alzheimer disease dementia syndrome is uncommon. We hypothesized that Alzheimer disease pathology is uncommon in MS patients. In 100 MS patients, the rate of amyloid-β plasma biomarker positivity was approximately half the rate in 300 non-MS controls matched on age, sex, apolipoprotein E proteotype, and cognitive status. Interestingly, most MS patients who did have amyloid-β pathology had features atypical for MS at diagnosis. These results support that MS is associated with reduced Alzheimer disease risk, and suggest new avenues of research. ANN NEUROL 2024;96:453–459.

UR - http://www.scopus.com/inward/record.url?scp=85197917351&partnerID=8YFLogxK

U2 - 10.1002/ana.27027

DO - 10.1002/ana.27027

M3 - Article

C2 - 38963256

AN - SCOPUS:85197917351

SN - 0364-5134

VL - 96

SP - 453

EP - 459

JO - Annals of neurology

JF - Annals of neurology

IS - 3

ER -

Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients

Abstract

Access to Document

Other files and links

Fingerprint

Cite this